XENON PHARMACEUTICALS INC (XENE)

GARY PATOU, a director at $XENE, sold 1,322 shares of the company on 06-05-2026 for an estimated $70,251. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.0% of their shares of this class of stock. Following this trade, they now own 24,896 shares of ...

Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $77.20. ... NASDAQ:XENE opened at $51.21 on Tuesday. Xenon Pharmaceuticals Inc. has a twelve month low of $30.00 and a twelve month high of $63.95. The company has a market cap of $4.95 billio…

NASDAQ XENE traded down $0.52 on Monday, hitting $51.21. 1,181,045 shares of the company’s stock were exchanged, compared to its average volume of 1,258,214. The firm’s 50-day moving average price is $55.74 and its two-hundred day moving average price is $48.68. Xenon Pharmaceuticals Inc. has a fift…

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is one of the 10 Best Performing Canadian Stocks So Far in 2026. On May 12, 2026, JPMorgan analyst Tessa Romero raised the firm’s price target on Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to $80 from $77 and maintained an Overweight rating on the shares.

Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript